Effects of evolving lipid-lowering drugs on carbohydrate metabolism. (March 2018)

• Record Type: Journal Article
• Authors: Tsimihodimos, V.; Elisaf, M.
• Is Part Of: Diabetes research and clinical practice. Volume 137(2018)
• Page Start: 1
• Page End: 9
• Publication Date: 2018-03
• Subjects: Antisense oligonucleotides -- PCSK9 inhibitors -- Apolipoprotein CIII inhibitors -- CETP inhibitors -- Lp(a); Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2017.12.012
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: The understanding that statins reduce but not eliminate the cardiovascular risk associated with disturbed lipid metabolism and the existence of forms of dyslipidemia that are unresponsive or only partially responsive to statins have led to the development of many novel lipid-lowering drugs. Accumulating evidence suggests that the interplay between carbohydrate and lipid metabolism is bidirectional. Thus, any intervention that affects lipid metabolism has the potential to influence the homeostasis of glucose. In this review we summarize the available data on the effects of the evolving lipid-lowering drugs on carbohydrate metabolism.